Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Medicinas Complementárias
Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Chin Med ; 44(6): 1099-1110, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27627913

RESUMEN

Bearing pathologic and clinical similarities to human multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) is used as a murine model to test potential therapeutic agents for MS. Recently, we reported the protective effects of an acidic polysaccharide of Panax ginseng (APG) in C57BL/6 strain-dependent EAE, a model of primary progressive MS. In this study, we extend our previous findings on the therapeutic capacity of APG in relapsing-remitting EAE (rr-EAE), the animal model to closely mimic recurrent inflammatory demyelination lesions of relapsing-remitting MS. Treatments with APG led to a significant reduction of clinical symptoms and the relapse rate of EAE than vehicle treatments. Consistent with this, histological examination revealed that APG markedly modulated the infiltration of CD4[Formula: see text] T cells and CD11b[Formula: see text] macrophages into the spinal cord and the APG-treated CNS was devoid of demyelination and axonal damages. In addition, APG decreased the proliferation of peripheral PLP-reactive T cells and the production of pro-inflammatory factors such as IFN-[Formula: see text], IL-17 and TNF-[Formula: see text]. The fact that APG can induce clinically beneficial effects to distinct types of EAE furthers our understanding on the basis of its immunosuppression in EAE and, possibly, in MS. Our results suggest that APG may serve as a new therapeutic agent for MS as well as other human autoimmune diseases, and warrants continued evaluation for its translation into therapeutic application.


Asunto(s)
Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Panax/química , Fitoterapia , Polisacáridos/farmacología , Polisacáridos/uso terapéutico , Animales , Antígeno CD11b , Linfocitos T CD4-Positivos/inmunología , Células Cultivadas , Enfermedades Desmielinizantes , Modelos Animales de Enfermedad , Femenino , Humanos , Macrófagos/inmunología , Ratones Endogámicos C57BL , Esclerosis Múltiple/tratamiento farmacológico , Polisacáridos/aislamiento & purificación , Recurrencia , Médula Espinal/inmunología , Médula Espinal/patología
2.
Acta Histochem ; 116(3): 514-21, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24380494

RESUMEN

Owing to its susceptibility to radiation, the small intestine of mice is valuable for studying radioprotective effects. When exposed to radiation, intestinal crypt cells immediately go through apoptosis, which impairs swift differentiation necessary for the regeneration of intestinal villi. Our previous studies have elucidated that acidic polysaccharide of Panax ginseng (APG) protects the mouse small intestine from radiation-induced damage by lengthening villi with proliferation and repopulation of crypt cells. In the present study, we identified the molecular mechanism involved. C57BL/6 mice were irradiated with gamma-rays with or without APG and the expression levels of apoptosis-related molecules in the jejunum were investigated using immunohistochemistry. APG pretreatment strongly decreased the radiation-induced apoptosis in the jejunum. It increased the expression levels of anti-apoptotic proteins (Bcl-2 and Bcl-XS/L) and dramatically reduced the expression levels of pro-apoptotic proteins (p53, BAX, cytochrome c and caspase-3). Therefore, APG attenuated the apoptosis through the intrinsic pathway, which is controlled by p53 and Bcl-2 family members. Results presented in this study suggest that APG protects the mouse small intestine from irradiation-induced apoptosis through inhibition of the p53-dependent pathway and the mitochondria/caspase pathway. Thus, APG may be a potential agent for preventing radiation induced injuries in intestinal cells during radio-therapy such as in cancer treatment.


Asunto(s)
Apoptosis , Yeyuno/efectos de los fármacos , Extractos Vegetales/farmacología , Polisacáridos/farmacología , Traumatismos Experimentales por Radiación/tratamiento farmacológico , Protectores contra Radiación/farmacología , Animales , Proteínas Reguladoras de la Apoptosis/metabolismo , Caspasa 3/metabolismo , Femenino , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/efectos de la radiación , Yeyuno/patología , Yeyuno/efectos de la radiación , Ratones Endogámicos C57BL , Mitocondrias/efectos de los fármacos , Mitocondrias/efectos de la radiación , Panax/química , Extractos Vegetales/uso terapéutico , Polisacáridos/uso terapéutico , Traumatismos Experimentales por Radiación/patología , Tolerancia a Radiación/efectos de los fármacos , Protectores contra Radiación/uso terapéutico
3.
Immunol Lett ; 138(2): 169-78, 2011 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-21524666

RESUMEN

An acidic polysaccharide of Panax ginseng (APG), so called ginsan, is a purified polysaccharide. APG has multiple immunomodulatory effects of stimulating natural killer (NK) and T cells and producing a variety of cytokines that proved to diminish the proinflammatory response, and protect from septic lethality. To determine APG's role in the autoimmune demyelinating disease, we tested whether APG can regulate inflammatory and encephalitogenic response in experimental autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis (MS). Here, we demonstrate the therapeutic efficacy of the APG which induces the suppression of an encephalitogenic response during EAE. APG significantly ameliorates the progression of EAE by inhibiting the proliferation of autoreactive T cells and the production of inflammatory cytokines such as IFN-γ, IL-1ß and IL-17. More importantly, APG promotes the generation of immunosuppressive regulatory T cells (Tregs) through the activation of transcription factor, Foxp3. Furthermore, the depletion of CD25+ cells from APG-treated EAE mice abrogates the beneficial effects of EAE. The capacity of APG to induce clinically beneficial effects furthers our understanding of the basis for its therapeutic immunosuppression of EAE and, possibly, MS. Thus, our results suggest that APG may serve as an effective therapy for MS and other autoimmune diseases.


Asunto(s)
Autoinmunidad/efectos de los fármacos , Encefalomielitis Autoinmune Experimental , Factores de Transcripción Forkhead/metabolismo , Inmunosupresores/farmacología , Panax/química , Polisacáridos/farmacología , Linfocitos T Reguladores/inmunología , Células TH1/inmunología , Animales , Proliferación Celular/efectos de los fármacos , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Encefalomielitis Autoinmune Experimental/genética , Encefalomielitis Autoinmune Experimental/inmunología , Encefalomielitis Autoinmune Experimental/patología , Femenino , Factores de Transcripción Forkhead/genética , Humanos , Inmunosupresores/uso terapéutico , Interferón gamma/biosíntesis , Interleucina-10/biosíntesis , Interleucina-17/biosíntesis , Activación de Linfocitos/efectos de los fármacos , Depleción Linfocítica , Ratones , Ratones Endogámicos C57BL , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/genética , Esclerosis Múltiple/inmunología , Esclerosis Múltiple/patología , Extractos Vegetales/química , Polisacáridos/uso terapéutico , Linfocitos T Reguladores/efectos de los fármacos , Células TH1/efectos de los fármacos , Transcripción Genética/efectos de los fármacos , Transcripción Genética/inmunología , Activación Transcripcional/efectos de los fármacos , Activación Transcripcional/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA